us regulator rule pain drug us food drug regulator will decide friday whether recommend sale painkiller link high risk heart attack stroke food drug administration fda advisory panel will give verdict hearing evidence three day painkiller call cox2 inhibitor sell brand name celebrex vioxx vioxx withdrawn shop last year merck say consider sell get fda approval fda ask decide benefit patient justify increase risk put vioxx back shelf likely boost profit merck make easy legal battle people claim injured drug analyst say merck voluntarily stop sale vioxx 30 september move cause firm fourthquarter earnings slide 11bn 581m 14bn year earlier mercks share tumble 10 news company set aside million dollar cover cost vioxxrelated litigation alarm bell rung research note call approve show risk heart attack stroke double patient take drug least 18 month cox2 inhibitor developed drug company include merck pfizer cause user stomach problem painkiller pfizer still sell celebrex bextra product though investigation suggest may also harmful heart mercks announcement possible reintroduction vioxx caught analyst surprise mercks head research peter kim say withdrew vioxx base information available us time know alternative therapy go say thing since change light new report give new information clear cardiovascular risk observe approve make vioxx unique class similar drug market us mr kim explain thursday david graham fda office drug safety told advisory panel really appear need cox2 inhibitor accord calculation present us senate dr graham november vioxx may link many 56000 american death face stem criticism handle vioxx case fda say tuesday will create independent body oversee safety drug already market place european regulator meanwhile rule thursday patient heart disease stroke take cox2 inhibitor european medicine agency also say doctor cautious give drug patient risk factor heart disease 